PCa critically depends on the prostate lineage factor androgen receptor (AR), making androgen deprivation therapy (ADT) the primary treatment that targets androgen signaling.[8] While initially effective, ADT often leads to most PCa patients eventually developing CRPC, a stage at which treatment options become significantly limited. Here, AR is linked to posterior cortical atrophy.